Palmer Luckey’s SLAB: Offshore Industry and U.S. Law14 min read2,873 words

Palmer Luckey’s SLAB: Offshore Industry and U.S. Law

Palmer Luckey’s SLAB aims to move industry offshore. Learn what the project proposes, what U.S. law still covers, and why medical access remains complicated.

Palmer Luckey SLABoffshore industry regulationseasteading lawoffshore medical researchU.S. maritime jurisdiction
Palmer Luckey’s SLAB: Offshore Industry and U.S. Law

Palmer Luckey's SLAB: What an Offshore Industrial Base Could - and Couldn't - Change

An industrial platform in the ocean sounds like a clean escape from rules written for land. Palmer Luckey - the Oculus founder who later founded defense technology company Anduril - has spent years talking about SLAB. His basic idea is to create room for American industry to operate with fewer state and local constraints. He's also said he wants people to access medicine that's currently illegal in the United States.

That leads to a practical question, not just an ideological one: what actually changes when a business goes offshore, and what laws follow it? The answer depends on where the platform is, whether it floats or is fixed to the seabed, who runs it, and what it plans to do. Crossing a line on a map doesn't automatically make the law stop.

Luckey says SLAB has been in development for nearly a decade and that it was backed at a $1 billion valuation in 2017. But he hasn't publicly disclosed the project's location, construction status, operating plan, or target date. This article separates what he's said from what's verifiable, lays out the main legal limits on offshore operations, and explains why "offshore medicine" is a particularly hard test. There's no clear, disclosed blockchain component to SLAB; if crypto is relevant here, it's only in the broader sense of how regulation, jurisdiction, and new infrastructure interact.

What is Palmer Luckey's SLAB project?

SLAB is Luckey's proposed offshore industrial platform, which he's described as a seastead with a design life of 1,000 years. In a November 2026 post on X, he said the concept grew out of money he received after Facebook acquired Oculus in 2014. He described the goal as building an industrial base that could be cheaper than land and less constrained by state and local rules.

He's pointed to activities that could include metal processing, oil refining, medical research, and treatment. That's a wide range, and it matters because each activity has very different needs - energy, transport, worker safety, environmental controls, and regulatory approval. A platform built for heavy industry wouldn't automatically be set up for clinical research, and vice versa.

What the project's public description does - and does not - tell us

Luckey has said he and close associates backed the project at a $1 billion valuation in 2017 and that significant progress has been made. Those two points aren't the same. A valuation describes how a venture was priced at a moment in time. It doesn't tell you how much money has actually gone into construction, where the project stands physically now, or what it still needs to finish.

The announcement included an AI-generated illustration, not photos or other evidence of an operating facility. Luckey also said he chose to reveal SLAB after hearing it might be described as a floating AI data center - something he considered too narrow. In his framing, SLAB is older and broader than that label.

For now, several basic details are still missing publicly:

  • A confirmed location or jurisdiction
  • Whether the structure would float, be anchored, or be attached to the seabed
  • Which industries would move in first
  • What specific rules the project is trying to avoid (if any)
  • Independent evidence of construction progress
  • A construction or operating timeline

Those gaps matter because the legal and business analysis shifts depending on the design. A floating vessel, a fixed platform, and an artificial island aren't interchangeable categories. With those details unclear, SLAB is best treated as a stated ambition, not a project whose regulatory situation can be evaluated end-to-end.

Why does Luckey want an offshore industrial base?

Luckey describes SLAB as an industrial policy project: a way to make certain types of production more feasible - or cheaper - in the United States by moving them away from land-based restrictions. He's called it a "relief valve" for rules he thinks are outdated and argued that state and local regulation is holding back "critical industries."

There's a real-world premise under that argument. Big industrial projects can hit long permitting timelines, local opposition, high land costs, and overlapping requirements. For projects with large upfront costs, delays aren't minor. They can raise financing costs, change construction schedules, and even decide whether a company proceeds at all. In theory, an offshore base could offer more access to ports, different logistics, and a different permitting path.

The cost comparison is more complicated than land versus ocean

"Cheaper than land" depends on what the full operating model looks like. Building at sea may avoid some land acquisition costs, but it introduces others: marine engineering, corrosion protection, storm resilience, maintenance access, power and water systems, worker transport, emergency response, and supply-chain logistics. For heavy industry, you also need reliable connections to raw materials, customers, and utilities.

The real comparison isn't the cost of building the platform versus the price of a plot. It's the total cost of producing and shipping goods over the facility's useful life, including insurance, maintenance, downtime, and compliance. A design life of 1,000 years is an engineering goal, not proof that the business case works in the first decade.

Regulatory flexibility is not the same as deregulation

Where an offshore site is located - and how it's classified legally - might reduce some local zoning rules or state-level processes. But that doesn't mean everything else disappears. Federal rules, maritime obligations, environmental requirements, and the rules attached to a vessel's flag state can still apply. And even when a rule isn't strictly compelled, companies often still follow standards because customers, insurers, lenders, and workers expect it.

There's also a governance trade-off. Slashing slow or duplicative approvals can help projects move. But removing safeguards without replacing them can push costs onto workers, patients, nearby communities, or the public. The key question isn't just whether a rule exists - it's what harm that rule is meant to address, whether it works, and what mechanism would take over if it's taken out.

That distinction matters even more when the proposed activity involves medicine. In a dispute with journalist Joshua Topolsky, Luckey said he'd rather create a place where people could access "safe but currently illegal medicine" than wait for political reform. That's a goal statement, but it doesn't specify which medicine, what safety standard counts, or who would decide whether the medicine is actually safe.

Does SLAB put its operators outside U.S. law?

Not automatically. Offshore jurisdiction is layered. Distance from shore can matter, but so do the platform's location, physical form, use, ownership, and registration.

Luckey has said, for example, that a site operating three miles from San Francisco wouldn't fall under the city's jurisdiction. Three miles lines up with a commonly cited boundary for state-controlled coastal waters in California - but boundaries like that aren't a universal "switch" that turns U.S. law off.

State waters, territorial sea and exclusive economic zone

The U.S. Bureau of Ocean Energy Management describes state coastal waters as generally extending three nautical miles from shore, though boundaries can vary. The U.S. territorial sea extends to 12 nautical miles. Beyond that, the U.S. exclusive economic zone can extend up to 200 nautical miles in areas where it applies.

These zones do different legal work. A coastal state's authority doesn't end exactly the same way federal authority does. Federal jurisdiction can extend beyond state waters, and the U.S. retains certain rights and responsibilities in the exclusive economic zone - including authority over specified economic activity and artificial islands. NOAA explains the general maritime zones, but which rules apply to a particular installation depends on the facts and on the law that governs that type of activity.

The takeaway is straightforward: three miles might be relevant to a state boundary, but it isn't an offshore exemption from U.S. law. Federal statutes can apply beyond state waters, and specific activities can fall under different legal authorities.

The platform's physical form and registration matter

A floating platform that qualifies as a vessel can be subject to maritime rules and the jurisdiction of its flag state. A structure attached to the seabed raises different questions from a mobile vessel. And an artificial island doesn't become its own sovereign country just because it's built at sea. An operator can't create a brand-new legal system by declaring the platform independent.

International maritime rules, national laws, and the terms of permits or registrations can all come into play. The framework may also differ between construction, day-to-day operations, and movement of people and goods. That's why design isn't just a technical detail: it helps determine what legal analysis applies.

For a real project, the first legal work wouldn't be "find the farthest point from shore." It would mean mapping the proposed location and activity against the relevant federal, state, maritime, and international frameworks. The operators would also need to understand which laws attach to the company, the vessel, the workers, the products, and the customers - not just the coordinates.

What could offshore medical treatment actually change?

Moving a clinic or research operation offshore might change which authorities have direct oversight of certain on-site activities. But it doesn't automatically make an unapproved medicine legal for sale in the United States. It also doesn't remove the ethical and operational issues that make medical experimentation risky in the first place.

Luckey's exchange with Topolsky was about whether building a new offshore community could speed medical progress. Topolsky argued that reform could happen without a platform, and asked what rules blocked a specific advance. Luckey's response was that legislative change can be slow and politically difficult, pointing to the challenge of securing support from 60 senators for some forms of reform.

That exchange highlights a real tension: patients may face serious unmet needs while regulators and lawmakers move cautiously. But "faster" isn't automatically "safer" or "more effective." The real question is whether a proposed system can protect participants, generate reliable evidence, and make clear what patients are consenting to.

Research standards follow the evidence, not the marketing claim

The U.S. Food and Drug Administration expects foreign clinical studies submitted in support of U.S. drug approvals to meet good clinical practice standards, including independent ethical review and informed consent. An offshore location doesn't make those expectations irrelevant. If a sponsor wants data that can support a U.S. approval, the study has to meet applicable requirements.

Research also needs to separate experimental treatments from established therapies. A patient's willingness to try something isn't proof on its own that it's safe. Independent review, transparent protocols, reliable records, and clear reporting of adverse events help protect participants and make results useful to others.

Treatment access and U.S. distribution are separate questions

Even if an offshore facility offers a treatment, that doesn't automatically settle whether the product can be imported, marketed, or prescribed in the United States. Those are separate legal questions. A company that runs a trial offshore still may face FDA requirements if it wants U.S. approval or wants to treat U.S. patients with the resulting product.

There are also practical constraints: emergency care, continuity of treatment, patient transport, insurance, responsibility for complications, and follow-up after someone returns home. Those aren't niche details. They determine whether a treatment program can deliver care safely beyond the moment patients board a vessel or sign a consent form.

So the phrase "safe but currently illegal medicine" leaves the core questions untouched. Which medicine? Illegal under what law? "Safe" according to what evidence? Available to whom, under what clinical supervision, and with what plan if something goes wrong? Until SLAB identifies a specific treatment and an operating model, it's not possible to tell whether the proposed route improves access or just relocates risk.

What is known - and still unverified - about SLAB?

The facts that are publicly available are limited, and it helps to separate them from interpretation. Luckey says the project began after Facebook acquired Oculus, has been in development for nearly a decade, and received backing at a $1 billion valuation in 2017. He's described a 1,000-year design life and an ambition to support industrial activity with fewer state and local constraints. He's also said medical access is part of the motivation.

What isn't public is just as important. No location, detailed engineering plan, construction deadline, named medical program, or independently verifiable progress report has been disclosed in the source account. The AI-generated image gives an impression, not proof that the illustrated platform exists or matches a final design.

What a credible next update would need to show

For investors, workers, potential patients, and regulators, an update that's actually useful would include more than another rendering or another broad claim about regulatory freedom. It would say:

  • Structure and site: whether SLAB is a vessel, a fixed installation, or another design - and where it would be located.
  • Operating model: what activities start first, who operates them, and how people and materials reach the facility.
  • Regulatory map: which approvals or rules apply, which are disputed, and what safeguards would replace any requirements the project wants to avoid.
  • Capital and delivery: how the 2017 valuation relates to current financing, construction milestones, and projected operating costs.
  • Medical governance: if treatment is planned, the therapies involved, how independent review would work, how consent would be handled, and how emergency care would be handled.

This isn't a demand that a private project spill every commercial detail. It's the minimum needed to assess whether the plan is primarily an industrial platform, a medical research program, a financing proposition, or some mix of all three.

Previous seasteading efforts show why implementation matters. A floating community off Thailand led to a confrontation with authorities in 2019. Another project in Panama used boat registration to operate within an existing legal framework. Those aren't direct predictions for SLAB, but they do show that ocean-based projects still have to work through state and maritime systems.

For now, the strongest conclusion is a limited one: SLAB is a proposed project with ambitious claims and unresolved details. Its eventual impact will depend less on the word "offshore" than on engineering, location, legal structure, and operating choices. Until those details are disclosed, claims about lower cost, freedom from regulation, or medically safer access remain unproven.

Conclusion

SLAB puts a familiar question into an unusual setting: can a business dodge land-based regulatory constraints by moving offshore? Maybe some state and local rules would change. But federal authority, maritime law, and requirements tied to products and customers don't vanish at the shoreline.

The same logic applies to medicine. Faster access could matter, especially for patients with few options. But a change of location doesn't replace evidence, informed consent, independent review, and a workable plan for complications. Those standards are part of making treatment trustworthy, not just barriers to route around.

In the end, the project should be judged on specifics: where it will operate, what it will do, which rules apply, and how it protects people. Until Luckey provides those details, SLAB remains an ambitious proposal - not proof that offshore industry can be cheaper, legally unbound, or medically safer.

Frequently Asked Questions

SLAB is a proposed offshore industrial platform that Palmer Luckey says could support activities such as metal processing, oil refining, medical research and treatment. He has described it as a seastead with a 1,000-year design life. Its location, construction status and operating timeline have not been publicly confirmed.
Luckey has rejected the description of SLAB as simply a floating AI data centre, saying the project predates that characterization and has broader ambitions. Public information does not establish the platform’s final design or initial use. The AI-generated illustration shared with the announcement is not evidence of an operating facility.
Not simply by moving beyond state waters. Federal jurisdiction, maritime law, vessel registration and rules governing activities in the exclusive economic zone may still apply. The outcome depends on location, structure, ownership and what happens on the platform. Offshore distance alone does not create an independent legal territory.
No. Conducting treatment offshore does not by itself make a drug legal to sell or distribute in the United States. The FDA also expects foreign clinical studies used to support U.S. drug approvals to meet good clinical practice standards, including informed consent and independent ethical review.
The public account does not provide independently verifiable evidence of construction, a confirmed site or a completion date. Luckey has said there has been significant progress, but the type and extent of that progress have not been detailed publicly. A funding valuation does not establish construction status or total project spending.

Related articles